Roberts M M, Juttner C A, To L B, Kimber R J
Division of Haematology, Royal Adelaide Hospital, South Australia.
Leuk Res. 1988;12(10):817-21. doi: 10.1016/0145-2126(88)90035-5.
A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day 6 of induction chemotherapy in 44 patients with AML treated with daunorubicin, cytosine arabinoside and thioguanine. Biopsies were assessed for blast count, trephine cellularity and leukaemic index. Discrimination between patients who went on to achieve remission and those with resistant disease was best achieved using the reduction in bone marrow cellularity from pretreatment marrow to day-6 marrow. However, this discriminator identified only 50% of the patients with resistant disease and included 13% of patients who achieved remission with the first course of chemotherapy. The other parameters of response were even less effective at discriminating between chemotherapy-resistant and chemotherapy-responsive disease.
开展了一项研究，以确定在急性髓系白血病（AML）诱导治疗第6天进行骨髓活检，是否能够识别出那些患有耐药性疾病、需要强化首个诱导疗程的患者。对44例接受柔红霉素、阿糖胞苷和硫鸟嘌呤治疗的AML患者，在诱导化疗第6天进行了骨髓活检。对活检标本评估原始细胞计数、骨髓组织细胞密度和白血病指数。从预处理骨髓到第6天骨髓的骨髓细胞密度降低情况，最有助于区分后续实现缓解的患者和患有耐药性疾病的患者。然而，这一判别指标仅识别出50%的耐药性疾病患者，且纳入了13%首个化疗疗程即实现缓解的患者。其他反应参数在区分化疗耐药性疾病和化疗反应性疾病方面效果更差。
